title: Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
authors: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University , Brno , Czech Republic.
authors: Daniela
authors: D
authors: Zackova
authors: Hana
authors: H
authors: Klamova
authors: Jan
authors: J
authors: Muzik
authors: Eduard
authors: E
authors: Cmunt
authors: Zdenek
authors: Z
authors: Racil
authors: Katerina
authors: K
authors: Machova Polakova
authors: Dana
authors: D
authors: Dvorakova
authors: Tomas
authors: T
authors: Jurcek
authors: Filip
authors: F
authors: Razga
authors: Petr
authors: P
authors: Cetkovsky
authors: Ladislav
authors: L
authors: Dusek
authors: Jiri
authors: J
authors: Mayer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D000069439:Dasatinib; D057915:Drug Substitution; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib